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Abstract
Background: Angiopoietin-2 (Ang-2) is associated with lung injury in ALI/ARDS. As endothelial activation by thrombin plays
a role in the permeability of acute lung injury and Ang-2 may modulate the kinetics of thrombin-induced permeability by
impairing the organization of vascular endothelial (VE-)cadherin, and affecting small Rho GTPases in human pulmonary
microvascular endothelial cells (HPMVECs), we hypothesized that Ang-2 acts as a sensitizer of thrombin-induced
hyperpermeability of HPMVECs, opposed by Ang-1.
Methodology/Principal Findings: Permeability was assessed by measuring macromolecule passage and transendothelial
electrical resistance (TEER). Angiopoietins did not affect basal permeability. Nevertheless, they had opposing effects on the
thrombin-induced permeability, in particular in the initial phase. Ang-2 enhanced the initial permeability increase (passage,
P = 0.010; TEER, P = 0.021) in parallel with impairment of VE-cadherin organization without affecting VE-cadherin Tyr685
phosphorylation or increasing RhoA activity. Ang-2 also increased intercellular gap formation. Ang-1 preincubation
increased Rac1 activity, enforced the VE-cadherin organization, reduced the initial thrombin-induced permeability (TEER,
P = 0.027), while Rac1 activity simultaneously normalized, and reduced RhoA activity at 15 min thrombin exposure
(P = 0.039), but not at earlier time points. The simultaneous presence of Ang-2 largely prevented the effect of Ang-1 on TEER
and macromolecule passage.
Conclusions/Significance: Ang-1 attenuated thrombin-induced permeability, which involved initial Rac1 activation-
enforced cell-cell junctions, and later RhoA inhibition. In addition to antagonizing Ang-1, Ang-2 had also a direct effect itself.
Ang-2 sensitized the initial thrombin-induced permeability accompanied by destabilization of VE-cadherin junctions and
increased gap formation, in the absence of increased RhoA activity.
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Introduction
Excessive and sustained activation of the pulmonary endothe-
lium is central in the pathogenesis of the pulmonary inflammation
and permeability of the life-threatening syndromes acute lung
injury (ALI) and acute respiratory distress syndrome (ARDS) [1].
In experimental models of ALI, the angiopoietin-Tie2 receptor
system modulates the responsiveness of the pulmonary endothe-
lium [2–5]. Indeed, angiopoietin-1 (Ang-1) reduced pulmonary
inflammation and permeability [2–8], whereas its antagonist
angiopoietin-2 (Ang-2) sensitized the pulmonary endothelium to
inflammatory stimuli [9,10]. Consistent with these experimental
data, circulating Ang-2 related to vascular permeability and
pulmonary dysfunction in critically ill patients [11–13].
Activation of coagulation is both a consequence and a
contributor to ALI/ARDS, since the pro-coagulant state results
in intra-alveolar fibrin deposition, which enhances inflammation
[14]. Furthermore, the pro-coagulant protein thrombin is
massively generated during ALI [15] and has direct effects on
vascular permeability via intercellular gap formation [16–18].
Interestingly, Ang-1 attenuated the thrombin-induced permeabil-
ity in human umbilical vein and bovine pulmonary endothelial
cells [19–21]. Nevertheless, the effect of Ang-2 on the thrombin-
response has not been studied. In addition, ALI/ARDS was not
appropriately modeled using those cell types, since endothelial cells
from different vascular beds display remarkable heterogeneity in
structure and function [22–24]. Therefore, it remains to be
investigated in an in vitro model of ALI using human pulmonary
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microvascular endothelial cells (HPMVECs), whether Ang-2
modulates the thrombin-induced permeability and which path-
ways are involved.
The effect of the Ang-2 on the kinetics of the thrombin response
is of specific interest, since different molecular mechanisms play a
role during the distinct phases of the response [16]. Indeed, during
the initial rapid increase in permeability after thrombin stimula-
tion, disruption of adherence junctions between cells, amongst
others due to reduced Rac1 activity [25] and subsequently RhoA-
mediated endothelial contraction [26], play a role [16,27]. When
the maximum increase in permeability is reached, both disruption
of adherence junctions and endothelial contraction play a role
[16,26].
For the current study it was hypothesized that Ang-2 increases
basal and thrombin-induced permeability of HPMVECs by
impairing vascular endothelial cadherin (VE-cadherin) junctional
organization in part via reduced Rac1 and increased RhoA
activity. Since Ang-1 has been extensively studied before, Ang-2
data were compared to Ang-1 data.
Materials and Methods
Isolation and culture of HPMVECs
HPMVECs were isolated as previously described (supporting
information Text S1) [24]. Five days after isolation, HPMVECs
formed small islands in culture. Nine days after isolation,
HPMVEC islands were confluent. After a second magnetic
separation of HPMVECs and non-endothelial cells, the culture
showed a purity of .99% as confirmed by the presence of
endothelial cell markers VE-cadherin, CD31, von Willebrand
factor (VWF), Tie2 and endothelial nitric oxide synthase (eNOS)
and the absence of smooth muscle cell (SMC) marker a-actin and
epithelial cell marker pancytokeratin (supporting information
Figure S1). HPMVECs had a relatively low basal permeability,
compared to human umbilical vein endothelial cells (HUVECs,
basal transendothelial electrical resistance (TEER) 41.363.0
V?cm2 vs. 27.663.8 V?cm2, P= 0.014).
Determination of the angiopoietin release of HPMVECs
Microvascular endothelial cell medium-2 (EGM-2-MV, Lonza,
Basel, Switzerland) was put on a confluent HPMVEC monolayer
for 0, 24, 48 or 72 hours. At each time point, medium was
collected and Ang-2 and Ang-1 concentrations were measured in
duplicate using the human Ang-2 and Ang-1 DuoSet ELISA
Development kits (R&D systems, Minneapolis, Minneapolis, USA)
according to the manufacturers protocol. Experiments were also
performed in cells stimulated with 0.1 U/ml thrombin to measure
endogenous Ang-2 release.
Determination of the endothelial permeability
In vitro, endothelial permeability can be evaluated by culturing
cells on porous filters and subsequent assessment of the horse
radish peroxidase (HRP, 40 kDa) passage or the transendothelial
ion-flux via cell-cell and cell-matrix contacts as indicated by the
TEER [28,29]. Since the relationship between the macromolecule
flux and the TEER is non-linear and the passage is size-dependent
[28–30] both were assessed.
The transfer of HRP over the HPMVEC monolayer was
measured as previously described [26–28]. In brief, confluent
monolayers of HPMVECs (passage 3–7) were harvested with
trypsin/ethyleendiaminetetraacetic acid (EDTA) and seeded in
high density on fibronectin-coated polycarbonate filters of the
Transwell system (0.33 cm2, pore size 3.0 mm, Corning Incorpo-
rated Life Sciences, Lowell, Massachusetts, USA). EGM-2-MV
medium with 5% fetal bovine serum was renewed every other day.
Monolayers were used 5 days after seeding. One hour before the
start of the experiment, monolayers were serum starved in 1%
human serum albumin (HSA, Sanquin, Amsterdam, The Nether-
lands) in endothelial cell basal medium-2 (EBM-2, Lonza). At the
start of the experiment (time= -30 min), HRP (5 mg/ml) with or
without Ang-2 (400 ng/ml), Ang-1 (400 ng/ml) or the combina-
tion in 1% HSA was added to the upper compartment of the
Transwell system. At time= 0 min, the first sample from the lower
compartment was taken and an equal volume of 1% HSA was
added to the lower compartment. Immediately after the first
sample was taken, thrombin (0.2 U/ml, Sigma, St. Louis,
Missouri, USA) was added to the upper compartment. The other
samples from the lower compartment were taken at time= 15, 30,
90 and 210 min. At the end of the experiment, a sample was taken
from the upper compartment. Filters were kept at 37uC under 5%
CO2/95% air atmosphere during the experiment. The concen-
tration of HRP was derived from the HRP activity in each sample
with peroxide and tetramethylbenzidine as substrate. The basal
HRP passage at t = 0 min (% of HRP input/hour) and the initial
and the prolonged HRP passage rate from 0–15 and from 30–
90 min after thrombin addition, respectively, were calculated.
The TEER was measured as previously described [28].
HPMVECs were seeded on the Transwell system as described
above. After serum starvation, Ang-2 (400 ng/ml), Ang-1
(400 ng/ml) or the combination was added to the upper
compartment of the filter and the filter was placed in the TEER
apparatus (t =230 min). The filter was left in the apparatus for
10 min to acclimatize before recording started. An alternating
current (50 mA, 2 pulses per min) was passed across the monolayer
by two source electrodes. The potential difference across the
monolayer was measured by two detecting electrodes. Thrombin
(0.2 U/ml) was added to the upper compartment of the filter at
t = 0 min. The recording continued until t = 40 min. Filters were
kept at 37uC under 100% air atmosphere during the experiment.
The electrical resistance was calculated by Ohm’s law and
expressed in VNcm2. Electrical resistance of the filter without an
endothelial monolayer (8 VNcm2) was subtracted from all measured
values. The absolute basal TEER at t = 0 min, the thrombin-
induced decrease in TEER per min from 0–10 min after
thrombin-stimulation and the prolonged maximum thrombin-
induced decrease in TEER were calculated.
Analysis of Tie2 and vascular endothelial cadherin (VE-
cadherin) phosphorylation
After serum starvation, Ang-2 (400 ng/ml), Ang-1 (200 ng/ml)
or the combination were added to the well chamber. Cells were
lysed with lysis buffer (20 mM Tris/HCl pH 8.0, 150 mM NaCl,
90 mM KCl, 2 mM EDTA/NaOH pH 8.0, igepal (1:200), triton
X-100 (1:200), 1 M Na3VO4, 10 mM NaF, protease inhibitors
(1:100), phosphatase inhibitors (1:100)) as previously described
[31] 15, 30 or 60 min after angiopoietin treatment for Tie2
phosphorylation or 1, 5 or 15 min after thrombin stimulation for
VE-cadherin phosphorylation. Tie2 phosphorylation was deter-
mined both in whole cell lysates and on immunoprecipitated Tie2
protein. VE-cadherin phosphorylation was determined in whole
cell lysates. Tie2 antibody (goat, R&D systems) was used for
immunoprecipitation as previously described [32]. In brief, cell
lysates of equal amounts of protein in 1 ml of lysisbuffer as
described above were incubated overnight at 4uC with the anti-
human Tie2 (4 mg/sample) antibody (R&D systems). The protein-
immunoglobulin G (IgG) complexes were pulled down using
protein A/G agarose beads (Santa Cruz Biotechnology, Santa
Cruz, USA) and after 3 washing steps laemmli buffer (Bio-Rad
Angiopoietins, Thrombin & Endothelial Permeability
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Laboratories, Hercules, California, USA) was added to the
immunoprecipitated Tie2 protein. Total cell lysates containing
equal amounts of protein or immunoprecipitated Tie2 protein
from each sample were separated by SDS-PAGE and electropho-
retically transferred to a nitrocellulose membrane (Bio-Rad
Laboratories). Membranes were incubated with polyclonal
antibodies against phosphorylated Tie2 (pTie2, Y1100, rabbit,
1:333, R&D systems), phosphorylated tyrosine (pTyr, mouse,
1:333, Cell signaling technology, Inc., Danvers, Massachusetts,
USA), total Tie2 (tTie2, goat, 1:500, R&D systems), phosphory-
lated VE-cadherin (tyrosine 685, rabbit, 1:200, ECM Biosciences,
Versailles, Kentucky, USA) or total VE-cadherin (rabbit, 1:1000,
Sigma). Total Tie2 and VE-cadherin were used as loading control.
Goat anti-rabbit, goat anti-mouse and rabbit anti-goat immuno-
globulins HRP (DakoCytomation, Glostrup, Denmark) were used
for the detection of the primary antibodies at 1:1000. Detection of
the HRP reaction was performed with ECL plus Western Blotting
Detection System (Amersham Biosciences, Little Chalfont Buck-
inghamshire, United Kingdom). Imaging and analysis were
performed with LAS-3000 (Fuji Photo Film Co., Ltd., Tokyo,
Japan) and AIDA Image Analyzer (Raytest GmbH, Strauben-
hardt, Germany). Data were expressed as phospho/total as
fraction of control.
Immunofluorescence
The cells were grown on gelatin-coated glass cover slips, treated
for 30 min with angiopoietins (400 ng/ml) followed by thrombin
stimulation (0.2 U/ml) for 2 and 15 min, fixed in 4% formalde-
hyde and permeabilized with 0.2% triton X-100. Cells were
incubated with antibodies against VE-cadherin (1:200, rabbit,
overnight, 4uC, Sigma). Alexa fluor 488 goat anti-rabbit (1:100,
Invitrogen, Carlsbad, California, USA) was used for the detection
of the primary VE-cadherin antibody. Actin filaments (F-actin)
were stained with rhodamin-phalloidin (1:100, Molecular Probes,
Inc., Eugene, Oregon, USA). The nucleus was stained with 49,6-
diamidino-2-phenylindole (DAPI) in VectashieldH Mounting
medium (Vector Laboratories, Inc., Burlingame, California,
USA). Cells were visualized with help of fluorescence microscopy
using a MarianasTM digital imaging microscope with 40X air lens
(Carl Zeiss B.V., Sliedrecht, The Netherlands) and Slidebook 4.2
software (Intelligent Imaging Innovations, Inc., Denver, Colorado,
USA).
To quantify the total gap area from VE-cadherin staining, so-
called maskes were created as described previously [33], a mask
being a binary overlay on an optical section. All VE-cadherin
derived fluorescent signal below a threshold was included in a
mask. The value for this threshold intensity was set manually
below the baseline fluorescence intensity so as to select the total
area negative for VE-cadherin, corresponding to the sites of inter-
endothelial gaps. To exclude negative pixels that belonged to
cellular regions, the individual fragments in the mask were gated to
a minimal area of 50 pixels. Finally, the total area of all individual
mask-fragments together was computed and expressed as a
percentage of the total area of the field of view.
G-LISATM Rac1 or RhoA activation assay
The Rac1 and RhoA protein activity were measured with help
of the G-LISATM Rac1 or RhoA activation assay (Cytoskeleton,
Inc., Denver, Colorado, USA) according to the manufacturers
protocol. After one hour serum starvation with 1% HSA in EBM-
2, cells were pre-incubated with Ang-2 (400 ng/ml), Ang-1
(400 ng/ml) or the combination for 30 min. After pre-incubation,
thrombin (0.2 U/ml) was added and Rac1 or RhoA activity were
measured 0, 1 or 15 min after addition of thrombin.
Statistical analysis
Basal HRP passage, the HRP passage/hour and the decrease in
TEER/min were not normally distributed (Kolmogorov-Smirnov
test, P,0.05). To obtain normal distribution, data were logarith-
mically transformed prior to statistical analysis. A one-way analysis
of variance (ANOVA) was conducted to explore the effects of the
angiopoietins. The Student’s t-test was used to further analyze the
differences between the groups when ANOVA indicated statistical
significance. Differences were considered significant at the P,0.05
level. Exact P-values are reported when P,0.05. Data are
presented as mean6standard error of the mean (SEM).
Results
Endogenous Ang-2 production
Under basal conditions, HPMVECs released Ang-2, but not
Ang-1 in their medium at a constant rate of 139614 pg/cm2/
hour (P,0.0001) for at least 72 hours, so that after 48 hours
,67 ng/ml Ang-2 was measured. To evaluate the effect of Ang-2,
cells were serum-starved in fresh EBM-2 medium with 1% HSA
one hour before the experiments, so that they were exposed to
maximum ,1.4 ng/ml endogenous Ang-2 before recombinant
Ang-2 was administered. An Ang-2 concentration of 400 ng/ml
was chosen for the experiments. Thrombin stimulation resulted in
an release of as little as 0, 2.6 and 2.9 ng/ml endogenous Ang-2 at
1, 5 and 10 min after stimulation, respectively, suggesting a
negligible effect of endogenous Ang-2 in the thrombin-induced
permeability response. The detectable amount of Ang-2 in the
conditioned medium decreased to 0.73 ng at 15 min after
thrombin stimulation, suggesting degradation or binding of
endogenous Ang-2.
Basal effects of angiopoietins
Unexpectedly, neither Ang-2, nor Ang-1 affected the basal
endothelial barrier function as determined by HRP passage
(Figure 1a) or TEER (Figure 1b). This was found with Ang-1 and -
2 concentrations ranging from 5 to 400 ng/ml. To exclude that
this was due to the short stimulation period (30 min), HPMVECs
were stimulated with Ang-2 for 5 hours. Even after 5 hours, Ang-2
(5–400 ng/ml) did not affect the basal permeability as measured
by the TEER (data not shown).
To confirm that the angiopoietins were able to activate the Tie2
receptor, Tie2 receptor phosphorylation was analyzed. Ang-1
induced a transient increase in Tie2 phosphorylation at the Y1100
tyrosine residue with a maximum increase at 15 and 30 min
(Figure 1c and 1d). A similar pattern was observed for the total
tyrosine phosphorylation of immunoprecipitated Tie2 (Figure 1c).
Y1100 Tie2 phosphorylation returned to basal levels at 60 min
(96627% of control). Co-treatment with Ang-2 blocked the Ang-
1-induced Y1100 Tie2 phosphorylation at 15 and 30 min
(Figure 1d). Ang-2 alone did not affect Y1100 Tie2 phosphory-
lation under our experimental conditions (Figure 1d).
Since RhoA and Rac1 are effectors of pTie2 [6,13], their
activity in HPMVECs under basal conditions 30 min after
angiopoietin addition was measured. Ang-1 did not affect basal
RhoA (93610% of control, n = 8) and enhanced basal Rac1
activity (12367% of control, P = 0.011, n= 6). Ang-2 did not
affect basal RhoA (110612% of control, n = 8), but the trend was
opposite to that of Ang-1. Ang-2 hardly affected Rac1 activity
(10863% of control, P = 0.034, n= 6). Thrombin was used as a
positive control. After 1 min exposure to thrombin RhoA activity
was enhanced 3.760.3-fold (P,0.0001, n = 7), while Rac1 activity
was reduced to 76610% of control (P = 0.0256, n= 5).
Angiopoietins, Thrombin & Endothelial Permeability
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Angiopoietin-induced modulation of the early thrombin-
response
Subsequently, the effects of Ang-2 and Ang-1 on the thrombin-
induced endothelial permeability were investigated. Differences in
the effects of angiopoietin pre-treatment on the initial and the
prolonged thrombin-induced endothelial permeability were ob-
served (Figure 2a,e).
Ang-2 enhanced the initial thrombin-induced HRP passage rate
from 0–15 min after thrombin addition, while Ang-1 or the
combination of Ang-1 and Ang-2 did not affect it (Figure 2c). In
contrast, neither Ang-2, nor Ang-1 affected the prolonged
thrombin-induced HRP passage rate from 30–90min (Figure 2d).
Since the TEER may be more sensitive to subtle thrombin-
induced changes [28,34], the effects of the angiopoietins on the
thrombin-induced TEER decrease in both phases were also
investigated (Figure 2f,g,h). The initial rate of the TEER decrease
from 0–10 min after thrombin addition was enhanced by Ang-2
and the combination of Ang-1 and Ang-2 and reduced by Ang-1, a
similar pattern as observed in the HRP passage experiments
(Figure 2g). The prolonged maximum decrease in TEER was not
affected by Ang-2 or the combination, while it was reduced by
Ang-1 (Figure 2h).
Angiopoietins modulate VE-cadherin redistribution by
thrombin
The observation that the angiopoietins modulate in particular
the initial response of endothelial cells to thrombin suggests that
angiopoietins may affect the molecular organization of the
adherence junctions [35]. To study the molecular organization
of the adherence junctions, VE-cadherin was visualized by
immunofluorescence microscopy as shown at 2 and 15 min after
thrombin stimulation in Figures 3a and b, respectively. VE-
cadherin was encountered in control cells as a continuous and
narrow lining at cell-cell borders reflecting stable junctions.
Exposure to thrombin induced a redistribution of VE-cadherin
into a zigzag wide pattern typical for unstable and activated
junctions and the generation of intercellular gaps. Ang-1
preincubation attenuated the effect of thrombin on VE-cadherin
redistribution and gap formation. However, still some intercellular
gaps were visible in accordance with the thrombin-induced
permeability in Ang-1 treated cells (Figure 3c). In contrast, the
effect of thrombin was enhanced in Ang-2 treated cells, which
resulted in even wider VE-cadherin staining and a stronger zigzag
pattern together with more intercellular gaps (Figure 3c). Ang-1
prevented the enhancement of gap formation in Ang-2 treated
Figure 1. Effect of angiopoietins (Ang) on basal permeability, Tie2 phosphorylation and RhoA activity of human pulmonary
microvascular endothelial cells (HPMVECs). Data are presented as mean6standard error of the mean. NS: not significant. a. Neither Ang-2, nor
Ang-1 affected the basal horse radish peroxidase (HRP) passage as measured 30 min after their addition (n = 7–9). b. Neither Ang-2, nor Ang-1
affected the basal transendothelial electrical resistance (TEER) as measured 30 min after their addition (n = 9–17). c. Representative western blots of
pTie2, tTie and immunoprecipitated (IP) tyrosine phosphorylated (pTyr) and total Tie2 are shown. d. Ang-1 induced a transient increase in the
phosphorylated Tie2 (pTie2)/total Tie2 (tTie2) ratio, with a maximum at 15 and 30 min after its addition (*P = 0.0046, **P = 0.0003). Ang-2 blocked the
Ang-1-induced increase in Tie2 phosphorylation at 15 and 30 min (#P= 0.0073, ##P= 0.0134, n = 5–9). Ang-2 alone did not affect Y1100 Tie2
phosphorylation.
doi:10.1371/journal.pone.0023448.g001
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cells (Figure 3c). The response at 2 and 15 min was similar,
although the thrombin-induced gaps were more pronounced at
15 min.
The changes in VE-cadherin were accompanied by alterations
in the F-actin cytoskeleton. While in control cells most F-actin
bundles were seen in the periphery of the cell, thrombin induced
the formation of F-actin bundles throughout the cell. However,
although there was a counteracting tendency by the presence of
Ang-1, the effects of Ang-1 and Ang-2 on thrombin-stimulated
stress fiber formation were very limited (Figure 3a and b).
We subsequently evaluated tyrosine phosphorylation of VE-
cadherin [18,35], with specific emphasis on that of the tyrosine
685 residue, since this residue is phosporylated by Src [35], which
is linked to angiopoietin signaling in the context of vascular
endothelial growth factor (VEGF)-induced endothelial permeabil-
ity [36]. VE-cadherin phosphorylation at tyrosine 685 was not
affected by thrombin stimulation, independent of angiopoietin
treatment (supporting information Figure S2).
Angiopoietins and RhoA and Rac1 activity in thrombin
stimulated cells
Disruption of the adherence junctions between cells may be
amongst others due to reduced Rac1 activity [25], and indirectly
influenced by RhoA-mediated actin-myosin interaction [26]. Since
both small GTPAses are described as effectors downstream of Tie2
phosphorylation [5,12], Rac1 and RhoA activities were deter-
mined at various time points ranging from 1 to 15 min after
thrombin addition. Rac1 activity was decreased at 1 min after
thrombin stimulation (Figure 4a) and normalized after 15 min
(Figure 4b), independently of the presence of angiopoietins. In
contrast, thrombin induced a 3- to 4-fold increase in RhoA activity
after 1 min compared to control (Figure 5a), which gradually
decreased to 3-fold after 15 min (Figure 5b). While the increase of
RhoA after 1 min was not altered by the presence of angiopoietins
(Figure 5a), RhoA activity at 15 min decreased more rapidly when
Ang-1 or the combination were present. This effect was absent in
cells treated with Ang-2 (Figure 5b).
Discussion
The main finding of the present study is that the angiopoietins
Ang-2 and Ang-1 had opposing effects on the very initial, but not
on the prolonged late phase of the thrombin-induced hyperperme-
ability response of cultured human pulmonary microvascular
endothelial cells. Specifically, Ang-2 enhanced the initial hyper-
permeability, while Ang-1 reduced the initial hyperpermeability by
attenuation of thrombin-induced reorganization of the adherence
junctions. The limited effect of angiopoietins on basal permeability
as compared to thrombin-stimulated permeability suggests that in
the adult endothelium the angiopoietin-Tie2 system is a sensitizer
of the activated endothelium in the presence of other inflamma-
tory or coagulation mediators, rather than an independent actor of
the permeability response. This is in line with previous findings
Figure 2. Effect of angiopoietins (Ang) on initial and prolonged permeability of human pulmonary microvascular endothelial cells
(HPMVECs) during thrombin stimulation. Data are presented as mean6standard error of the mean. NS: not significant. a. An averaged curve of
horse radish peroxidase (HRP) passage of control cells stimulated with thrombin (IIa) at time= 0 min, showing the typical s-shape (n = 9). Cells were
stimulated with angiopoietins (A) at time=230 min. The initial HRP passage rate from time= 0–15 min and the prolonged HRP passage rate from
time= 30–90 min were calculated as indicated by the vertical dashed lines. b. Representative experiment (in triplo) showing averaged curves of HRP
passage of control and angiopoietin-stimulated cells. Cells were stimulated with angiopoietins at time=230 min and with thrombin at time= 0 min.
c. Ang-2 increased the initial HRP passage rate (*P = 0.010), while Ang-1 or the combination did not affect it (n = 7–9). d. Neither Ang-2, nor Ang-1
affected the prolonged HRP passage rate (n = 8–9). e. An averaged curve of the transendothelial electrical resistance (TEER) of control cells stimulated
with thrombin at time= 0 min (n = 17). Cells were stimulated with angiopoietins at time=230 min. The initial rate of TEER decrease from time= 0–10
min and the prolonged maximum TEER decrease were calculated as indicated by the vertical dashed lines. f. Representative experiment (in triplo)
showing averaged curves of the TEER of control and angiopoietin-stimulated cells. Cells were stimulated with angiopoietins at time=230 min and
with thrombin at time= 0 min. g. Ang-2 and the combination enhanced the initial rate of the TEER decrease (**P = 0.021, #P= 0.036), while Ang-1
reduced it (*P = 0.027, n = 12–16). h. Ang-2 or the combination did not affect the prolonged maximum TEER decrease, while Ang-1 reduced it
(*P,0.0001, n = 12–16).
doi:10.1371/journal.pone.0023448.g002
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that Ang-2 alone did not affect the adhesion of leukocytes to
quiescent endothelium, while it promoted adhesion of leukocytes
to endothelial cells activated by tumor necrosis factor-a [10].
The permeability enhancing effect of thrombin in endothelial
monolayers in culture can be separated in two phases. During the
initial phase (0–15 min) the TEER decreases rapidly, while the
passage of HRP starts increasing. During this phase the
endothelial junctions become instable and locally small gaps
between the cells are formed. After 15 min stress fibers have
become formed reflecting a major change in the F-actin-
cytoskeleton. In the subsequent phase (15–90 min) the rate of
HRP passage becomes maximal. This phase includes continued
actin-myosin interaction within the cells and cell contraction
[16,37]. However, the TEER starts to recover during this period
suggesting that junctional complexes and focal adhesion sites are
locally recovering, although still relatively large gaps between cells
remain. After 90 min a full recovery of the monolayer is observed
both with regard to TEER and HRP passage.
In the context of this dual effect of thrombin, the effect of
angiopoietins only on the initial thrombin response is of interest
and points to an effect at the junctional level in particular. Indeed,
we observed changes in VE-cadherin localization that reflected
unstable junctions and intracellular gap formation. While similar
alterations in adherence junctions and VE-cadherin relocalization
are induced by VEGF via Src phosphorylation at Tyr685 and
subsequent activities [35], thrombin did not affect this phosphor-
ylation. This is accordance with Kinney et al. [38], who showed
that thrombin has no effect on Src and Yes, but only on the Src-
like protein Fyn, which has less permeability enhancing properties
[39]. Apparently another mechanism induces the dissociation of
VE-cadherins in adherence junctions.
Notwithstanding, our data support previous findings that Ang-1
inhibits the thrombin response by enforcement of junctions via
enforcement of the VE-cadherin-catenin complex [19], similar as
observed in VEGF- and bradykinin-induced hyperpermeability
[36,40–42]. After exposure of human endothelial cell monolayers
Figure 3. a, b and c. Effect of angiopoietins on the molecular organization of vascular endothelial cadherin (VE-cadherin) in human
pulmonary microvascular endothelial cells (HPMVECs). Immunofluorescence morphological analysis and quantification of the distribution of
VE-cadherin in control cells and cells treated with angiopoietins (Ang) and thrombin (IIa) for 2 (a) and 15 (b) min. Cells were stained with antibodies
specific for VE-cadherin (green), with rhodamin-phalloidin for actin filaments (F-actin, red) and with 496-diamidino-2-phenylindole (DAPI) for the
nuclei (blue). A 63x magnification is shown. The arrows indicate intercellular gaps. The left panel shows the VE-cadherin staining at the cell-cell
borders. The middle panel shows the F-actin cytoskeleton. The right panel shows the merge of VE-cadherin, F-actin and the nuclei. a. The thrombin
response after 2 min. b. The thrombin response after 15 min. c. Ang-2 enhances (*P,0.0001) and Ang-1 reduces (**P = 0.0257) the formation of
thrombin-induced interendothelial gaps (*P,0.0001 thrombin stimulation vs. control). Total gap area was determined as described in the methods
section. Data are the mean6standard error of the mean from at least 6 pictures per condition.
doi:10.1371/journal.pone.0023448.g003
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to Ang-1, Tie-2 receptors are mobilized from the endothelial cell
surface to the cell junctions, where oligo- or multimers of Ang-1
[43] bridge Tie-2 receptors of both adjacent cells [41,44]. This
complex also recruits vascular endothelial protein tyrosine
phosphatase (VE-PTP) [45]. At these junctions the multimeric
complex of Ang-1 and Tie-2 bridges two cells [41,44] and induces
specific Tie-2-mediated signaling that causes activation of small
GTPase Rap1 and subsequently Rac1, which enforce the
maintenance of the junctions between both cells [46-48]. Such
mechanism underlies the protective effect of Ang-1 on VEGF-
induced hyperpermeability [36,40,45] and on the initial thrombin
induced hyperpermeability as presently and previously observed
[19–21].
Several additional signaling mechanisms have been reported,
namely Ang-1 inhibited the thrombin response by reduction of the
cytoplasmic calcium concentration [49] or PKC-f activity [21,50].
In addition, Mammoto et al. [5] pointed towards an increased
activity of the inhibitory GTPase activating protein p190 RhoGAP
as a contributor to the inhibitory effect of Ang-1 on endotoxin-
mediated vascular leakage. As thrombin induces RhoA activity, a
similar mechanism may contribute to the effects observed in the
present HPMVECs. Activation of p190RhoGAP by Ang-1 limits
the activation of Rho kinase and mDia, which can affect
subsequent pathways that enhance permeability [5,36]. Indeed,
Ang-1 caused a reduction in RhoA activation when assayed
15 min after thrombin stimulation, conform Mammoto et al. [5],
but not at earlier time points (see also [20]). Therefore, modulation
of RhoA activity becomes in particular important when the
junctions were already destabilized by the initial response.
To our knowledge, we are the first to demonstrate that Ang-2
enhanced thrombin-induced endothelial permeability in
HPMVECs, similar to the effect of Ang-2 on VEGF-induced
Figure 4. Effect of angiopoietins (Ang) on Rac1 activity of thrombin (IIa)-stimulated human pulmonary microvascular endothelial
cells (HPMVECs). Data are presented as mean6standard error of the mean. a. Thrombin stimulation reduced Rac1 activity 1 min after stimulation
(*P = 0.0256), independent of angiopoietin treatment (n = 5–6). b. Rac1 activity was normalized 15 min after thrombin stimulation, independent of
angiopoietin treatment (n = 5–6).
doi:10.1371/journal.pone.0023448.g004
Figure 5. Effect of angiopoietins (Ang) on RhoA activity of thrombin (IIa)-stimulated human pulmonary microvascular endothelial
cells (HPMVECs). Data are presented as mean6standard error of the mean. NS: not significant. a. RhoA activity was increased 1 min after thrombin
addition (*P,0.0001), independent of angiopoietin treatment (n = 7–8). b. RhoA activity was still increased 15 min after thrombin addition
(*P,0.0001), but the increase became less in cells treated with Ang-1 (**P = 0.039, n = 6) or the combination (***P= 0.034, n = 6–8).
doi:10.1371/journal.pone.0023448.g005
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retinal endothelial cell permeability [51]. Interestingly, Ang-2
enhanced the initial permeability in particular, suggesting that
Ang-2 modulates the stability of the junctions before or during the
initial rapid increase in thrombin-induced permeability [16,18],
but has less effect during the later phase of the cell contraction
after formation of stress fibers, i.e. when the junctional multimeric
Ang-1/Tie-2 complexes had disappeared. Indeed, Ang-2 induced
a change in the molecular organization of the junctions as
demonstrated by an enhancement of the zigzag pattern, while it
did not enhance the number or organization of stress fibers during
thrombin stimulation. Ang-2 did not enhance VE-cadherin
phosphorylation at tyrosine 685, as seen in other conditions
[35]. However, the availability of Tyr685 depends on Csk binding
[52], while other VE-cadherin tyrosine residues may be phos-
phorylated by Ang-2 [35]. Alternatively, Ang-2 may act by
preventing protective actions on adherence junction proteins. In
line with this suggestion, Seegar et al. [53] reported that Ang-2
enhances Tie-1-Tie-2 interaction, which inhibits the endothelial
protective effect of Tie-2 activation. This in contrast to Ang-1,
which directs protective Tie-2 activity by homomultimerization
[53]. This latter action of Ang-1 probably also explains why the
combination of equal concentrations of Ang-1 and Ang-2, which
in most studies have equal affinities for the Tie2 receptor [54–56],
still enhanced the initial rate of the thrombin-induced permeabil-
ity, albeit slightly less than Ang-2 alone.
Whether the withdrawal of Tie-2 from junctional multimeriza-
tion also causes the increase in thrombin-induced hyperperme-
ability when only Ang-2 is added, is uncertain, because endothelial
cells produce little Ang-1 themselves [57]. Signaling by direct
interaction of Ang-2 with Tie-1 into the endothelial cell has also
been reported [58] and may affect junction stability in thrombin-
stimulated cells. Finally, Ang-2 can activate endothelial cells via
other phosphorylation sites on the Tie2 receptor [32], while the
interaction between the F-actin cytoskeleton and junctional
proteins may also be affected. RhoA is an important mediator of
thrombin-induced actin-myosin interaction, which also causes
stress fiber formation and cell contraction. Parikh et al. [12]
reported that Ang-2 increased basal permeability via increased
RhoA activity, but did not study the effect of Ang-2 on thrombin-
induced RhoA activity. In our experiments Ang-2 did not affect
the degree of RhoA activation at 15 min after thrombin-
stimulation or under basal conditions. However, it should be
noted that Parikh et al. [12] observed an unusual prolonged
increased RhoA activity up to 6 hours, which suggests that an
additional activation of the HPMVECs has occurred that affected
their responsiveness to Ang-2 [10].
The responses to Ang-1 and Ang-2 were relatively small. We
cannot not exclude that the HPMVECs had reduced sensitivity for
Ang-2, due to the endogenous production of Ang-2 by endothelial
cells themselves. Nevertheless, cells were stimulated with approx-
imately 6 times higher concentrations of Ang-2 than they
encountered normally during culture. Furthermore, it should be
noted that thrombin-induced macromolecule passage largely takes
place via the paracellular pathway through intercellular gaps and
depends on the molecular size of the macromolecule [28-30]. The
present data cannot completely exclude additional effects of the
angiopoietins on transcellular exchange.
In conclusion, the present study describes the effects of
angiopoietins related to the kinetics of the thrombin-response in
HPMVECs. The effects of angiopoietins are only found in the
initial junction-related thrombin-induced permeability and not in
the prolonged stress fiber contraction-related phase of thrombin-
induced permeability. As the latter phase is accompanied by
abundant stress fiber formation to an extent that is normally not
seen in vivo, it is likely that the initial phase provides a better
reflection of pathophysiological alterations of the endothelial
barrier. This fits with the current knowledge of the effect of Ang-1,
and our data add new information regarding a potential role of
Ang-2.
Supporting Information
Figure S1 Characterization of cultured human pulmo-
nary microvascular endothelial cells (HPMVECs). Phase-
contrast pictures of HPMVECs 5 and 9 days after isolation are
shown. Subsequent panels show representative fluorescent images
of vascular endothelial (VE)-cadherin, CD31, von Willebrand
factor (VWF), smooth muscle cell (SMC) a-actin and pancytoker-
atin and representative western blots of Tie2 and endothelial nitric
oxide synthase (eNOS).
(TIF)
Figure S2 Angiopoietins do not affect vascular endothe-
lial cadherin (VE-cadherin) phosphorylation of human
pulmonary microvascular endothelial cells (HPMVECs).
Representative western blots of VE-cadherin phosphorylated (p) at
tyrosine residue 685 and total VE-cadherin in control (C), Ang-1
(A1) and Ang-2 (A2) treated cells as measured 1, 5 and 15 min
after thrombin (IIa) addition.
(TIF)
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